<DOC>
	<DOCNO>NCT01359202</DOCNO>
	<brief_summary>This clinical trial enroll 110 patient approximately 15 Canadian stroke centre . Patients come emergency department bleed brain due trauma know cause treat within 6 hour onset undergo CT angiography use standard CT scanner ( `` CAT scan '' ) . Those `` spot sign '' , type marker CT scan show brain still bleed , randomly assign single injection `` factor 7 '' ( blood clot drug use hemophilia ) placebo ( inactive saline ) ; patient without spot sign treat . The researcher look much bleeding happen treatment administer , well clinical outcome death disability . The researcher think factor 7 cause bleed stop faster possibly decrease death disability .</brief_summary>
	<brief_title>`` Spot Sign '' Selection Intracerebral Hemorrhage Guide Hemostatic Therapy</brief_title>
	<detailed_description>This phase II double blind RCT enroll 110 patient approximately 15 Canadian stroke centre . Acute ICH patient treat within 6 hour onset undergo CT angiography use standard CT procedure . Those spot sign randomly assign 1:1 ratio single injection rFVIIa 80 Âµg/kg placebo ; patient without spot sign treat . The primary endpoint ICH expansion within 24 hour .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Inclusion Criteria Acute spontaneous primary supratentorial ICH diagnose CT scan . Presence spot sign within hematoma CTA source image Baseline ICH volume 390 ml Age 18 old Investigator able randomize administer study drug soon possible within target 60 minute CT angiogram later 6 hour stroke symptom onset ( use `` last see normal '' principle ) . Plan provide full medical care least 24 hour Assentconsent patient LAR prior enrolment , waiver consent ( REB approve ) patient/LAR assentconsent possible prior enrolment . Exclusion Criteria Brainstem cerebellar hemorrhage . ICH secondary know suspected trauma , aneurysm , vascular malformation , hemorrhagic conversion ischemic stroke , venous sinus thrombosis , thrombolytic treatment , tumour , infection ; inhospital ICH ICH result inhospital procedure illness . Baseline brain imaging show evidence acute subacute ischemic stroke ( chronic infarct exclusion ) . Contrast administration within previous 24 hour . Evidence thromboembolic risk factor , define following : know history within past 6 month follow : ( ) myocardial infarction , ( b ) coronary artery bypass surgery , ( c ) angina , ( ) ischemic stroke , ( e ) transient ischemic attack , ( f ) carotid endarterectomy , ( g ) cerebral bypass surgery , ( h ) deep venous thrombosis , ( ) pulmonary embolism , ( j ) vascular angioplasty , stenting ( coronary , peripheral vascular cerebrovascular ) filter ( e.g . vena cava filter ) ; ( k ) prosthetic cardiac valve ; and/or ( l ) know history highrisk thrombophilia ( e.g . antithrombin III deficiency , antiphospholipid antibody syndrome , protein C deficiency , etc . ) Known hereditary ( e.g . hemophilia ) acquire hemorrhagic diathesis coagulation factor deficiency . Any condition know investigator feel would pose significant hazard rFVIIa administer . Planned surgery ICH within 24 hour ( placement intraventricular catheter exclusion ) . Planned withdrawal care 24 hour postICH onset . Known participation another therapeutic trial . Known allergy contraindication iodinate contrast dye . Known suspected hypersensitivity trial product . Known unfractionated heparin use must check PTT exclude elevate upper limit local lab 's reference range . Known lowmolecular weight heparin , heparinoid , factor X inhibitor , direct thrombin inhibitor use within previous 7 day . Known GPIIb/IIIa antagonist use previous 2 week . Known warfarin ( anticoagulant ) therapy INR &gt; 1.40 . Note : patient suspect cirrhosis , study staff wait INR value prior dose , ensure enroll patient INR value &gt; 1.40 . Otherwise physician use discretion believe patient risk elevate INR . Concurrent plan treatment prothrombin complex concentrate , vitamin K , fresh frozen plasma , platelet transfusion . Pregnancy lactation . Women childbearing potential must negative pregnancy test prior randomization . Current clinical symptom suggestive acute coronary ischemia ( e.g . chest pain ) . Baseline ECG evidence acute coronary ischemia ( e.g . ST elevation 2 contiguous lead , new LBBB , ST depression ) . Baseline platelet count &lt; 50,000 INR &gt; 1.40 elevate PTT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Stroke</keyword>
	<keyword>ICH</keyword>
	<keyword>Intracerebral hemorrhage</keyword>
	<keyword>acute stroke</keyword>
	<keyword>rfVIIa</keyword>
	<keyword>Niastase</keyword>
</DOC>